Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
about
Radioisotopes for metastatic bone painPatient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastasesRadium-223 for the Management of Bone Metastases in Castration-Resistant Prostate CancerDiagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyWITHDRAWN: Radioisotopes for metastatic bone pain.Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases.Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone diseaseRadiotherapy for metastatic bone disease: current standards and future prospectus.Effective use of strontium-89 in osseous metastases.Radionuclide therapy beyond radioiodine.Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.A patient with esophageal cancer with bone metastasis who achieved pain relief with repetitive administration of strontium-89 chloride.Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.
P2860
Q24235589-4402D5C0-2BDA-4D26-950D-4EEF7B81E2C6Q26997330-86DC1976-8C1B-49E2-BFA9-C6A9B160333BQ28073320-37AA89F9-4C0E-4F42-BE64-C1828E8A2908Q28076646-AD11BEB5-9B17-4446-AF9B-DEB9832BC116Q33440341-8FFE52AF-9A57-453F-9B01-7E33BE1CE121Q36224128-20215814-F282-4787-8143-7A0A1A92682DQ37100364-DFA66845-FDFE-4710-BB11-1DA0ABF877D9Q37752373-FADC9A61-C93B-4567-9FCB-5C3F4649D46FQ37967436-5B76BD71-9DB3-4376-8243-418C28DD069EQ38027798-8C936F89-BA1E-4398-85B4-CE31A64A8680Q38297692-9F9C604C-2A39-4A4F-AFA7-4D921AAFE20CQ39186223-0672E75F-2957-432C-A0A3-2E238CF61A11Q41241592-6CB731CB-0D28-4AB4-9F01-DDFBDD0DBFC3Q43146234-4A9EC208-08B1-4C85-8C3D-6FF7172865F3Q49908522-114BE511-7C34-4980-A662-E66C65010F60
P2860
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
@en
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
@nl
type
label
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
@en
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
@nl
prefLabel
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
@en
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
@nl
P2093
P50
P1433
P1476
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases
@en
P2093
Alfredo Marinelli
Gaetano Paone
Leonardo Molino
Michele Klain
P356
10.1016/J.BONE.2005.12.004
P577
2006-01-24T00:00:00Z